GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy

American Journal of Nephrology

Volumn 38, Issue 1, 2013, Pages 39-49

  Heilig, Charles W ^a   Deb, Dilip K ^b   Abdul, Afu ^c   Riaz, Hasan ^a   James, Leighton R ^a   Salameh, Jamal ^a   Nahman, N Stanley ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diabetic nephropathy; Glomerulosclerosis; Glucose transporter; GLUT1; Growth factors; Vascular endothelial growth factor

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE; GLUCOSE TRANSPORTER 1; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

DIABETIC NEPHROPATHY; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; MEDIATOR RELEASE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 84879493776     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000351989     Document Type: Review

References (89)

1. USRDS: USRDS 2010 Annual Data Report. Bethesda, NIH, NIDDK, 2010.
2. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984; 74: 1143-1155.
3. Ibrahim HN, Hostetter TH: Diabetic nephropathy. J Am Soc Nephrol 1997; 8: 487-493.
4. Diabetes Control and Complications Trial Research Group (DCCT): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
6. Bilous RW, Mauer SM, Sutherland DE, Najarian JS, Goetz FC, Steffes MW: The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N Engl J Med 1989; 321: 80-85.
7. Chiarelli F, Gaspari S, Marcovecchio ML: Role of growth factors in diabetic kidney disease. Horm Metab Res 2009; 41: 585-593.
8. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P: Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 1995; 96: 1802-1814.
9. Vesely ED, Heilig CW, Brosius FC 3rd: GLUT1-induced cFLIP expression promotes proliferation and prevents apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 2009; 297:C759-C765.
10. Wang YHK, Saunders T, Minto A, Deb DK, Chang A, Brosius F, Monteiro C, Heilig CW: Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis. Am J Physiol Renal Physiol 2010; 299:F99-F111.
11. Wang Y, Heilig KO, Minto AW, Chen S, Xiang M, Dean DA, Geiger RC, Chang A, Pravtcheva DD, Schlimme M, Deb DK, Heilig CW: Nephron-deficient Fvb mice develop rapidly progressive renal failure and heavy albuminuria involving excess glomerular GLUT1 and VEGF. Lab Invest 2010; 90: 83-97.
12. Heilig K, Chen S, Xiang M, Brosius F, Heilig C: Overexpression of GLUT1 in glomeruli produces features of diabetic nephropathy in mice (abstract). J Am Soc Nephrol 2004; 15: 263A.
13. Heilig CW, Kreisberg JI, Freytag S, Murakami T, Ebina Y, Guo L, Heilig K, Loberg R, Qu X, Jin Y, Henry D, Brosius FC 3rd: Antisense GLUT-1 protects mesangial cells from glucose induction of GLUT-1 and fibronectin expression. Am J Physiol Renal Physiol 2001; 280:F657-F666.
14. Chen SHK, Brosius F 3rd, Heilig C: Diabetes increases glomerular GLUT1, and antisense-GLUT1 protects against diabetic glomerulosclerosis. J Am Soc Nephrol 2003; 14: 14A.
15. Manolescu AR, Witkowska K, Kinnaird A, Cessford T, Cheeseman C: Facilitated hexose transporters: new perspectives on form and function. Physiology (Bethesda) 2007; 22: 234-240.
16. Brosius FC 3rd, Briggs JP, Marcus RG, Barac-Nieto M, Charron MJ: Insulin-responsive glucose transporter expression in renal microvessels and glomeruli. Kidney Int 1992; 42: 1086-1092.
17. Heilig C, Zaloga C, Lee M, Zhao X, Riser B, Brosius F, Cortes P: Immunogold localization of high-affinity glucose transporter isoforms in normal rat kidney. Lab Invest 1995; 73: 674-684.
18. Heilig CW, Liu Y, England RL, Freytag SO, Gilbert JD, Heilig KO, Zhu M, Concepcion LA, Brosius FC 3rd: D -Glucose stimulates mesangial cell GLUT1 expression and basal and IGF-1-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes 1997; 46: 1030-1039.
19. Henry DN, Busik JV, Brosius FC 3rd, Heilig CW: Glucose transporters control gene expression of aldose reductase, PKCα, and GLUT1 in mesangial cells in vitro. Am J Physiol 1999; 277:F97-F104.
20. Heilig CW, Brosius FC 3rd, Cunningham C: Role for GLUT1 in diabetic glomerulosclerosis. Expert Rev Mol Med 2006; 8: 1-18.
21. Murakami T, Nishiyama T, Shirotani T, Shinohara, Y, Kan M, Ishii K, Kanai F, Nakazuru S, Ebina Y: Identification of two enhancer elements in the gene encoding the type 1 glucose transporter from the mouse which are responsive to serum, growth factor, and oncogenes. J Biol Chem 1992; 267: 9300-9306.
22. Hwang DY, Ismail-Beigi F: Control of Glut1 promoter activity under basal conditions and in response to hyperosmolarity: role of Sp1. Am J Physiol Cell Physiol 2006; 290:C337-C344.
23. Behrooz A, Ismail-Beigi F: Dual control of glut1 glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation. J Biol Chem 1997; 272: 5555-5562.
24. Xiang MHK, Nahman N, Heilig C: Mechanogrowth factor regulation by diabetes and GLUT1 in glomeruli (abstract). J Am Soc Nephrol 2010; 21: 167A.
25. Xiang MHK, James LR, Panni J, Nahman NS Jr, Heilig CW: Mechano-growth factor induces the mesangial cell GLUT1 glucose transport system. J Am Soc Nephrol 2011; 22: 471A.
26. Buller CL, Heilig CW, Brosius FC 3rd: GLUT1 enhances mTOR activity independently of TSC2 and AMPK. Am J Physiol Renal Physiol 2011; 301:F588-F596.
27. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S: Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007; 112: 417-428.
28. Carey RM, Siragy HM: The intrarenal reninangiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003; 14: 274-281.
29. Gnudi L, Thomas SM, Viberti G: Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J Am Soc Nephrol 2007; 18: 2226-2232.
30. Singh R, Singh AK, Alavi N, Leehey DJ: Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003; 14: 873-880.
31. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
32. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL: Characterization of protein kinase C β-isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997; 100: 115-126.
33. Rovin BH, Yoshiumura T, Tan L: Cytokineinduced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J Immunol 1992; 148: 2148-2153.
34. Weigert C, Brodbeck K, Brosius FC 3rd, Huber M, Lehmann R, Friess U, Facchin S, Aulwurm S, Haring HU, Schleicher ED, Heilig CW: Evidence for a novel TGF-β 1 -independent mechanism of fibronectin production in mesangial cells overexpressing glucose transporters. Diabetes 2003; 52: 527-535.
35. Nose A, Mori Y, Uchiyama-Tanaka Y, et al: Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: involvement of HB-EGF and EGF receptor transactivation. Hypertens Res 2003; 26: 67-73.
36. Di Simone N, Di Nicuolo F, Marzioni D, et al: Resistin modulates glucose uptake and glucose transporter-1 (GLUT-1) expression in trophoblast cells. J Cell Mol Med 2009; 13: 388-397.
37. Oppermann MF, Castrop H, Mizel D, Heilig K, Heilig C, Schnermann J: Glomerular hypertension and hyperfiltration in young fvb. ROP Os/+ mice. FASEB J 2007; 21: 595.28.
38. Pugliese G, Pricci F, Barsotti P, Iacobini C, Ricci C, Oddi G, Romeo G, Leto G, Marano G, Sorcini M, Sabbatini M, Fuiano G, Di Mario U, Pugliese F: Development of diabetic nephropathy in the Milan normotensive strain, but not in the Milan hypertensive strain: possible permissive role of hemodynamics. Kidney Int 2005; 67: 1440-1452.
39. Ricci C, Iacobini C, Oddi G, Amadio L, Menini S, Rastaldi MP, Frasheri A, Pricci F, Pugliese F, Pugliese G: Role of TGF-β/GLUT1 axis in susceptibility versus resistance to diabetic glomerulopathy in the Milan rat model. Nephrol Dial Transplant 2006; 21: 1514-1524.
40. Forbes JM, Fukami K, Cooper ME: Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007; 115: 69-84.
41. Souza MS, Machado UF, Okamoto M, et al: Reduced cortical renal GLUT1 expression induced by angiotensin-converting enzyme inhibition in diabetic spontaneously hypertensive rats. Braz J Med Biol Res 2008; 41: 960-968.
42. Arnoni CP, Lima C, Cristovam PC, Maquigussa E, Vidotti DB, Boim MA: Regulation of glucose uptake in mesangial cells stimulated by high glucose: role of angiotensin II and insulin. Exp Biol Med (Maywood) 2009; 234: 1095-1101.
43. Chen S, Jim B, Ziyadeh FN: Diabetic nephropathy and transforming growth factor-β: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003; 23: 532-543.
44. Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994; 93: 536-542.
45. Wolf G, Ziyadeh FN: The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997; 29: 153-163.
46. Riser BL, Cortes P, Heilig C, et al: Cyclic stretching force selectively up-regulates transforming growth factor-β isoforms in cultured rat mesangial cells. Am J Pathol 1996; 148: 1915-1923.
47. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993; 92: 2597-2601.
48. Border WA, Noble NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
49. Massague J, Wotton D: Transcriptional control by the TGF-β/Smad signaling system. EMBO J 2000; 19: 1745-1754.
50. Moustakas A, Heldin CH: The regulation of TGF-β signal transduction. Development 2009; 136: 3699-3714.
51. Wang W, Koka V, Lan HY: Transforming growth factor-β and Smad signalling in kidney diseases. Nephrology (Carlton) 2005; 10: 48-56.
52. Fujishiro M, Gotoh Y, Katagiri H, et al: MKK6/3 and p38 MAPK pathway activation is not necessary for insulin-induced glucose uptake but regulates glucose transporter expression. J Biol Chem 2001; 276: 19800-19806.
53. Yamamoto Y, Yoshimasa Y, Koh M, Suga J, Masuzaki H, Ogawa Y, Hosoda K, Nishimura H, Watanabe Y, Inoue G, Nakao K: Constitutively active mitogen-activated protein kinase kinase increases GLUT1 expression and recruits both GLUT1 and GLUT4 at the cell surface in 3T3-L1 adipocytes. Diabetes 2000; 49: 332-339.
54. Inoki K, Haneda M, Maeda S, Koya D, Kikkawa R: TGF-β 1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Kidney Int 1999; 55: 1704-1712.
55. Qi W, Chen X, Poronnik P, Pollock CA: Transforming growth factor-β/connective tissue growth factor axis in the kidney. Int J Biochem Cell Biol 2008; 40: 9-13.
56. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG: Advanced glycosylation end products up-regulate connective tissue growth factor (insulinlike growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 2001; 142: 1760-1769.
57. Qi W, Twigg S, Chen X, Polhill TS, Poronnik P, Gilbert RE, Pollock CA: Integrated actions of transforming growth factor-β 1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol 2005; 288:F800-F809.
58. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11: 25-38.
59. Murphy M, Crean J, Brazil DP, Sadlier D, Martin F, Godson C: Regulation and consequences of differential gene expression in diabetic kidney disease. Biochem Soc Trans 2008; 36: 941-945.
60. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999; 274: 5830-5834.
61. Foster RR: The importance of cellular VEGF bioactivity in the development of glomerular disease. Nephron Exp Nephrol 2009; 113:e8-e15.
62. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
63. Eremina V, Quaggin SE: The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004; 13: 9-15.
64. Sison K, Eremina V, Baelde H, Min W, Hirashima M, Fantus IG, Quaggin SE: Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 21: 1691-1701.
65. Villegas G, Lange-Sperandio B, Tufro A: Autocrine and paracrine functions of vascular endothelial growth factor in renal tubular epithelial cells. Kidney Int 2005; 67: 449-457.
66. Guan F, Villegas G, Teichman J, Mundel P, Tufro A: Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 2006; 291:F422-F428.
67. Bertuccio C, Veron D, Aggarwal PK, Holzman L, Tufro A: Vascular endothelial growth factor receptor-2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem 286: 39933-39944.
68. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla Casley DJ, Bach LA, Kelly DJ, Gilbert RE: Increased renal expression of vascular endothelial growth factor and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239.
69. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R: Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 3090-3094.
70. Nakagawa T: Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 2007; 292:F1665-F1672.
71. Ziyadeh FN, Wolf G: Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4: 39-45.
72. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
73. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S: Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093-3104.
74. Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF: Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996; 7: 661-666.
75. Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, Eichinger F, Gaiser S, Schmid H, Rastaldi MP, Schrier RW, Schlondorff D, Cohen CD: Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol 2007; 18: 1765-1776.
76. Sivaskandarajah GA, Jeansson M, Maezawa Y, Eremina V, Baelde HJ, Quaggin SE: VEGFA protects the glomerular microvasculature in diabetes. Diabetes 61: 2958-2966.
77. Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, Shen W, Kopp JB, Thomas DB, Tufro A: Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 2010; 77: 989-999.
78. Pfafflin A, Brodbeck K, Heilig CW, Haring HU, Schleicher ED, Weigert C: Increased glucose uptake and metabolism in mesangial cells overexpressing glucose transporter 1 increases interleukin-6 and vascular endothelial growth factor production: role of AP-1 and HIF-1α. Cell Physiol Biochem 2006; 18: 199-210.
79. Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN: Podocyte-derived vascular endothelial growth factor mediates the stimulation of α3(IV) collagen production by transforming growth factor-β 1 in mouse podocytes. Diabetes 2004; 53: 2939-2949.
80. Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, Gandhi NK, Danesh FR, Wolf G, Ziyadeh FN: Angiotensin II stimulates α3(IV) collagen production in mouse podocytes via TGF-β and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 2005; 20: 1320-1328.
81. Schneider MR, Wolf E: The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009; 218: 460-466.
82. Matrougui K: Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinase. Diabetes Metab Res Rev 2010; 26: 13-16.
83. Smith NJ, Chan HW, Osborne JE, Thomas WG, Hannan RD: Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. Cell Mol Life Sci 2004; 61: 2695-2703.
84. Alvarez RH, Kantarjian HM, Cortes JE: Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006; 81: 1241-1257.
85. Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM: Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol Dial Transplant 2003; 18: 1392-1396.
86. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper, ME: Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005; 16: 363-373.
87. Wang L, Hayashi H, Ebina Y: Transient effect of platelet-derived growth factor on GLUT4 translocation in 3T3-L1 adipocytes. J Biol Chem 1999; 274: 19246-19253.
88. Yuasa T, Kakuhata R, Kishi K, Obata T, Shinohara Y, Bando Y, Izumi K, Kajiura F, Matsumoto M, Ebina Y: Platelet-derived growth factor stimulates glucose transport in skeletal muscles of transgenic mice specifically expressing platelet-derived growth factor receptor in the muscle, but it does not affect blood glucose levels. Diabetes 2004; 53: 2776-2786.
89. Perez A, Ojeda P, Ojeda L, Ojeda L, Salas M, Rivas CI, Vera JC, Reyes AM: Hexose transporter GLUT1 harbors several distinct regulatory binding sites for flavones and tyrphostins. Biochemistry 2011; 50: 8834-8845.